Investment Firm Bets Big on Compass Therapeutics, Adds 2.5 Million Shares

Palo Alto Investors LP disclosed a new $13.6 million position in the clinical-stage biotech company.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

According to a recent SEC filing, Palo Alto Investors LP initiated a new position in Compass Therapeutics (NASDAQ:CMPX) during the fourth quarter of 2025, purchasing 2,532,419 shares worth an estimated $13.6 million. This new position accounts for nearly 2% of the investment firm's total assets under management.

Why it matters

Compass Therapeutics is a clinical-stage biotech company developing antibody-based cancer treatments, an area that has seen significant investor interest and potential for growth. Palo Alto Investors' sizable new position in the company suggests the firm sees significant upside potential in Compass's pipeline and future prospects.

The details

The filing shows Palo Alto Investors purchased the 2.5 million shares of Compass Therapeutics in Q4 2025, with the position valued at $13.6 million as of December 31st. This new stake in CMPX represents 1.89% of Palo Alto's total 13F assets under management.

  • Palo Alto Investors disclosed the new Compass Therapeutics position in a SEC filing dated February 17, 2026.
  • The shares were purchased during the fourth quarter of 2025, with the position valued at $13.6 million as of December 31, 2025.

The players

Palo Alto Investors LP

A California-based independent investment management firm that recently initiated a new $13.6 million position in Compass Therapeutics.

Compass Therapeutics, Inc.

A clinical-stage biotechnology company specializing in the development of novel antibody therapeutics for oncology indications.

Got photos? Submit your photos here. ›

The takeaway

Palo Alto Investors' sizable new position in Compass Therapeutics suggests the firm sees significant growth potential in the clinical-stage biotech company's pipeline of cancer-fighting antibody treatments. This transaction highlights the continued investor interest in the oncology and immunotherapy markets.